Condition
Pancreatic Cancer|Mesothelioma|Ovarian Cancer|Non-Small Cell Lung Cancer
Estimated Enrollment: 24
Age Group: 18 Years and older (Adult, Senior)
Gender: All
Study Type: Interventional
Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment
Study ID Numbers: MORAb-009-001
Study First Received: May 11, 2006
Last Updated: July 16, 2014
Estimated Primary Completion Date: September 2008
Primary Outcome Measures:
Safety and Tolerability as a measure of Adverse Events/Serious Adverse Events|Safety and Tolerability as a measure of clinical laboratory parameters|Safety and Tolerability as a measure of physical examinations, vital signs, and ECGs|Pharmacokinetics of MORAb-009|Percentage of Participants With Antibodies Against Infliximab (Human Anti-chimeric Antibody [HACA])|Objective Tumor Response Rate Assessed by Investigator
Sponsors and Collaborators:
Morphotek
Website Link: https://ClinicalTrials.gov/show/NCT00325494
